# Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. is an other based in Somerville, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Somerville, United States
- **Region:** North America
- **Address:** Somerville, Massachusetts, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** finchtherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/finch-therapeutics

## Regulatory record

- **Reports private funds:** No

## About

Founding year: 2017. David Berry, a Flagship Pioneering partner, incubated Finch as a Flagship venture, naming Mark Smith as an early executive. Smith returned as CEO in 2023 after a prior stint, replacing Geoff von Maltzahn. Wealth originates from Flagship Pioneering's venture model, not a single-operator fortune. Strategy: Finch focuses on microbiome-based therapies for infectious and autoimmune conditions. Its lead candidate, CP101 (currently in Phase 3), targets recurrent C. difficile infection. The firm also runs a PRISM platform for biologic discovery, engaging partnerships with Takeda and others. Its capital mix includes public equity (via Nasdaq: FNCH), debt facilities, and milestone payments from collaboration deals. Geographic footprint is US-centered, with clinical sites nationwide. Scale: The firm went public in 2021 at around $600M market cap. Recent 10-K filings show a cash runway extending into mid-2025, with no new disclosed funding rounds since 2022. Team size is not publicly detailed beyond C-suite titles. No disclosed additional offices. No philanthropic arm is separated. Structural differentiator: Finch operates as a public company with a single-asset focus — CP101. That creates a binary payout structure: either the Phase 3 trial succeeds and the asset gets commercialized, or capital evaporates. The Flagship-originated shell makes governance effectively a venture-backed public biotech, not a family office or traditional asset manager.

## Sectors

- Digital Health
- Biotech
- Therapeutics

## People

- Mark Smith — Chief Executive Officer
- David Berry — Board Member

## Questions

### Who runs investment decisions at Finch Therapeutics?

CEO Mark Smith runs strategic and capital-allocation decisions, with board oversight from Flagship Pioneering and independent directors. The firm's public structure means CFO and board approve major capital raises or partnership terms (per SEC filings).

### How does Finch source its therapeutic candidates?

Finch's PRISM platform screens human microbiome samples to identify bacterial consortia linked to therapeutic effects. CP101 was derived from a single donor's stool sample, and the firm uses data analytics to refine composition (per the firm's S-1 filing, 2021).

### Does Finch participate in fund commitments or only direct development?

Finch does not invest third-party capital. It is a development-stage company that raises equity and debt for its own pipeline. There is no fund structure or outside LP involvement.

### What investment stages does Finch typically target?

Finch targets clinical-stage proof-of-concept for microbiome therapies, not early seed or venture rounds. Its key focus is Phase 3 registration trials and potential commercialization.

### Which sectors does Finch explicitly avoid?

I don't have a reliable public source restricting Finch's sector focus beyond microbiome therapeutics. The firm does not disclose explicit avoidance areas.

### How is Finch related to Flagship Pioneering?

Flagship Pioneering incubated Finch in 2017 and remains a significant shareholder and board representative (David Berry). Flagship's model is venture creation — Finch was spun out as a separate entity with independent management and board (per Flagship's portfolio listing).

## Related profiles

- [Variant Alternative Income Fund](https://altss.com/profile/variant-alternative-income-fund)
- [VAT Group AG/ADR](https://altss.com/profile/vat-group-agadr)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/finch-therapeutics-group-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology